Corporate Fact Sheet 1H-2023

OVERVIEW

  • Focus on repurposing drugs for rare & infectious diseases
  • Advancing clinical development of Bucillamine for infectious diseases, including COVID-19 (FDA Phase 3)
  • Developing Psilocybin, MDMA and Cannabidiol therapeutics
  • Robust patent portfolio(15 patents and patent applications)
  • Awarded FDA Orphan Drug Status for CBD in the treatment of Autoimmune Hepatitis
  • Prioritize development efforts targeting FDA regulatory incentives designations (i.e. Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease)

PRODUCT PIPELINE

EXPECTED MILESTONES 1H-2023

Finalize FDA pathway of Phase 3 study and potential unblinding of data

Schedule of DSMB meeting for COVID-19 Phase 3 study primary endpoint

Phase 1/2 study - Psilocybin in Methamphetamine Disorder at University of Wisconsin

Manufacturing Psilocybin oral thin film strip for FDA IND

Manufacturing of MDMA patch for research purposes

CONTACT INFOMATION

Revive Therapeutics Ltd.

82 Richmond Street East

Toronto, ON M5C 1P1

Tel: 1-888-901-0036

E-mail:info@revivethera.com

Website:revivethera.com

STRATEGIC PARTNERS

TEAM

Management

Michael Frank, Chairman & CEO

Carmelo Marrelli, CFO

Derrick Welch, COO, Psilocin Pharma

Scientific and Clinical

Dr. Kelly McKee, CSO Dr. Arshi Kizilbash, M.D.

Dr. Osnesmo Mpanju, Regulatory Affairs

Dr. John Fahy, MD, Clinical and Scientific Advisor

Directors

Michael Frank, William Jackson, Joshua Herman, Christian Scovenna and Andrew Lindzon

STOCK INFORMATION

Ticker:

CSE: RVV, OTCQB: RVVTF,

FRANKFURT: 31R

Share Price:

$0.06 (March 22, 2023)

52-week High / Low:

CAD $0.49 / $0.04

Shares Outstanding:

356,237,674

Market Cap:

CAD ~ 22,000,000

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Revive Therapeutics Ltd. published this content on 23 March 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 March 2023 18:43:01 UTC.